Episode Details

Back to Episodes

Connecting the science and the business of drug innovation

Published 2 years ago
Description

Blockbuster drugs like Ozempic and Zepbound may appear to be overnight successes but were actually the result of years of research and incremental breakthroughs. In this podcast, Capital Group biopharmaceutical analyst Judith Finegold and investment director David Polak discuss how we have reached a renaissance in drug discovery, the changing dynamics of the global health care payments landscape and why successful investing in the biopharma industry requires deep understanding of not only the science but also the business dynamics. #CapGroupGlobal

 

 

For full disclosures go to capitalgroup.com/global-disclosures

 

 

 


For our latest insights, practice management ideas and more, subscribe to Capital Ideas at
getcapitalideas.com. If you're based outside of the U.S., visit

Listen Now